PMID- 32678359
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20220531
IS  - 1538-067X (Electronic)
IS  - 1092-1095 (Linking)
VI  - 24
IP  - 4
DP  - 2020 Aug 1
TI  - Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With 
      Mantle Cell Lymphoma.
PG  - 392-398
LID - 10.1188/20.CJON.392-398 [doi]
AB  - BACKGROUND: Acalabrutinib is a selective Bruton tyrosine kinase inhibitor 
      approved for patients with relapsed or refractory mantle cell lymphoma, an 
      aggressive B-cell malignancy. Treatment-related adverse events (AEs) can have a 
      negative effect on treatment adherence. OBJECTIVES: This article aims to provide 
      nurses with firsthand guidance so that they can better support patients with 
      mantle cell lymphoma initiating acalabrutinib. METHODS: Safety data from the 
      acalabrutinib ACE-LY-004 phase 2 trial in 124 patients with relapsed or 
      refractory mantle cell lymphoma were reviewed, and strategies implemented at the 
      University of Texas MD Anderson Cancer Center to manage trial AEs are described. 
      FINDINGS: The most common AEs of any grade were headache and diarrhea, but no 
      patients discontinued treatment because of them. When doses were missed or 
      modified, patients were reeducated about the importance of adherence and how to 
      manage AEs. Grade 1-2 AEs were managed with over-the-counter medication, if 
      needed. These strategies allowed for the tracking of occurrences of nonadherence, 
      providing the opportunity to advise and educate patients and to manage AEs more 
      effectively.
FAU - Badillo, Maria
AU  - Badillo M
AD  - University of Texas MD Anderson Cancer Center.
FAU - Nava, Diana
AU  - Nava D
AD  - University of Texas MD Anderson Cancer Center.
FAU - Rosa, Maria
AU  - Rosa M
AD  - University of Texas MD Anderson Cancer Center.
FAU - Chen, Wendy
AU  - Chen W
AD  - University of Texas MD Anderson Cancer Center.
FAU - Guerrero, Maria
AU  - Guerrero M
AD  - University of Texas MD Anderson Cancer Center.
FAU - Wang, Michael
AU  - Wang M
AD  - University of Texas MD Anderson Cancer Center.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin J Oncol Nurs
JT  - Clinical journal of oncology nursing
JID - 9705336
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzamides)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrazines)
RN  - I42748ELQW (acalabrutinib)
MH  - Adult
MH  - *Antineoplastic Agents/adverse effects
MH  - *Benzamides/adverse effects
MH  - Clinical Trials, Phase II as Topic
MH  - Humans
MH  - *Lymphoma, Mantle-Cell/drug therapy
MH  - Protein Kinase Inhibitors/*adverse effects
MH  - *Pyrazines/adverse effects
OTO - NOTNLM
OT  - Bruton tyrosine kinase
OT  - adherence
OT  - adverse event
OT  - mantle cell lymphoma
EDAT- 2020/07/18 06:00
MHDA- 2021/11/25 06:00
CRDT- 2020/07/18 06:00
PHST- 2020/07/18 06:00 [entrez]
PHST- 2020/07/18 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
AID - 10.1188/20.CJON.392-398 [doi]
PST - ppublish
SO  - Clin J Oncol Nurs. 2020 Aug 1;24(4):392-398. doi: 10.1188/20.CJON.392-398.